Ocugen to Provide Business Update and Third Quarter 2026 Financial Results on November 4
Ocugen (OCGN) will report third quarter 2026 financial results and provide a business update on November 4, 2026.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Ocugen (OCGN) will report third quarter 2026 financial results and provide a business update on November 4, 2026. The conference call and live webcast will begin at 8:30 a.m. ET. Related materials will be available on the company’s investor website before the call, with a replay and archived webcast available afterward.
Key Figures
- Results announcement date
- November 4, 2026
- Third quarter 2026 financial results and business update
AI-generated analysis. How Rhea-AI works. Not financial advice.
MALVERN, Pa., Oct. 22, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, will host a conference call and live webcast on Wednesday, November 4, 2026, at 8:30 a.m. ET to provide a business update and report third quarter 2026 financial results. All related materials will be made available on the Ocugen investor website prior to the start of the call.
Conference Call Details
Date: Wednesday, November 4, 2026
Time: 8:30 a.m. ET
Webcast: https://edge.media-server.com/mmc/p/w8rytgud
Participant Event Dial-ins: +1(800)715-9871 for US callers and +1(646)307-1963 for international callers
Participant Access Code: 6835403
A replay of the call and archived webcast will be available on the Ocugen investor website.
About Ocugen, Inc.
Ocugen, Inc. is a pioneering biotechnology company developing gene therapies for blindness diseases. The Company’s breakthrough modifier gene therapy platform has the potential to address significant unmet medical needs across large patient populations through a gene-agnostic approach. Unlike traditional gene therapies and gene-editing technologies that target a single gene mutation, Ocugen’s modifier gene therapies are designed to address the underlying disease biology by restoring balance across multiple gene networks. The Company is currently advancing programs for inherited retinal diseases and other causes of blindness that affect millions worldwide, including retinitis pigmentosa, Stargardt disease, and geographic atrophy, an advanced form of dry age-related macular degeneration. Discover more at www.ocugen.com and follow Ocugen on LinkedIn and X.
Cautionary Note on Forward-Looking Statements
This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995, which are subject to risks and uncertainties. We may, in some cases, use terms such as “predicts,” “believes,” “potential,” “proposed,” “continue,” “estimates,” “anticipates,” “expects,” “plans,” “intends,” “may,” “could,” “might,” “will,” “should,” or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. Such statements are subject to numerous important factors, risks, and uncertainties that may cause actual events or results to differ materially from our current expectations. These and other risks and uncertainties are more fully described in our filings with the Securities and Exchange Commission (SEC), including the risk factors described in the section entitled “Risk Factors” in the quarterly and annual reports that we file with the SEC. Any forward-looking statements that we make in this press release speak only as of the date of this press release. Except as required by law, we assume no obligation to update forward-looking statements contained in this press release whether as a result of new information, future events, or otherwise, after the date of this press release.
Contacts
Investors:
Candice Masse
astr partners
candice.masse@astrpartners.com
Media:
Chris Clark
VP Communications, Ocugen
chris.clark@ocugen.com
